Literature DB >> 35747024

Empagliflozin-Induced Pancreatitis: A Case Report Pattern.

Parker Foster1, Pinky Jha1, Sarbagya Pandit1.   

Abstract

Sodium-glucose cotransporter-2 inhibitors have become a great insulin-independent approach for diabetic management. These agents have increasingly been reported to be associated with the onset of acute pancreatitis. Here, we present a suspected case of empagliflozin-induced pancreatitis. Finally, we compile previous reports of suspected cases.
Copyright © 2022, Foster et al.

Entities:  

Keywords:  acute pancreatitis; adverse drug effect; case-based review; empagliflozin; sodium-glucose cotransporter-2 (sglt2) inhibitors

Year:  2022        PMID： 35747024      PMCID： PMC9209401          DOI： 10.7759/cureus.25189

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  8 in total

Review 1.  AGA Institute technical review on acute pancreatitis.

Authors:  Chris E Forsmark; John Baillie
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

2.  Empagliflozin-Induced Pancreatitis.

Authors:  Damon R McIntire; David B Bayne
Journal:  Ann Pharmacother       Date:  2018-07-02       Impact factor: 3.154

Review 3.  Drug-induced acute pancreatitis: a review.

Authors:  Mark R Jones; Oliver Morgan Hall; Adam M Kaye; Alan David Kaye
Journal:  Ochsner J       Date:  2015

4.  Adverse Side Effects: Empagliflozin-Related Acute Pancreatitis Case Report.

Authors:  Bassem S Zeidan; Charles Boadu; Andrea Hernandez; Johnathan Frunzi; Itioye Adetula
Journal:  Cureus       Date:  2020-12-27

Review 5.  Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.

Authors:  Anne F Peery; Seth D Crockett; Caitlin C Murphy; Jennifer L Lund; Evan S Dellon; J Lucas Williams; Elizabeth T Jensen; Nicholas J Shaheen; Alfred S Barritt; Sarah R Lieber; Bharati Kochar; Edward L Barnes; Y Claire Fan; Virginia Pate; Joseph Galanko; Todd H Baron; Robert S Sandler
Journal:  Gastroenterology       Date:  2018-10-10       Impact factor: 22.682

6.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

7.  Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Authors:  David Fitchett; Silvio E Inzucchi; Christopher P Cannon; Darren K McGuire; Benjamin M Scirica; Odd Erik Johansen; Steven Sambevski; Stefan Kaspers; Egon Pfarr; Jyothis T George; Bernard Zinman
Journal:  Circulation       Date:  2019-03-12       Impact factor: 29.690

8.  Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors.

Authors:  Karolina N Dziadkowiec; Peter M Stawinski; Jose Proenza
Journal:  ACG Case Rep J       Date:  2021-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.